Armed Cell Therapeutics Acquires Lakefront Therapy Assets
The deal moves the preclinical portfolio to new ownership as Lakefront pivots toward autoimmune T-cell engager research.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Do you trust that major pharmaceutical companies are effectively managing their research and development investments?
Armed Cell Therapeutics has acquired the preclinical cell therapy pipeline from Lakefront Biotherapeutics, formerly known as Galapagos Therapeutics. The deal follows Lakefront's decision to exit the cell therapy space entirely to concentrate on autoimmune T-cell engager programs.
Why it matters
This divestment marks the formal conclusion of a significant pivot for Lakefront Biotherapeutics after the closure of its cell therapy business resulted in a 228 million euro financial impact. The shift prioritizes T-cell engager research, a move backed by the company's largest shareholder, Gilead Sciences.
The transaction includes 8 million euros in upfront cash and up to 230 million dollars in milestone payments for the preclinical portfolio. This follows a previous 14 million dollar acquisition of AboundBio in 2022, which was integrated before the firm's total wind-down of cell therapy operations.
The players
Armed Cell Therapeutics
A biotechnology firm now overseeing the former Lakefront Biotherapeutics preclinical cell therapy pipeline.
Lakefront Biotherapeutics
Formerly Galapagos Therapeutics, this firm is pivoting to focus on autoimmune T-cell engager programs.
Gilead Sciences
A biopharmaceutical company holding a 25 percent stake in Lakefront Biotherapeutics and owner of Ouro Medicines.
Henry Gosebruch
The CEO of Lakefront Biotherapeutics who oversaw the exit from cell therapy development.
The details
Armed Cell Therapeutics will independently assume control of the preclinical cell therapy assets, moving away from the internal development model used by Lakefront. Lakefront is shifting its strategy toward T-cell engagers — engineered proteins designed to redirect T-cells to attack specific disease-causing cells. This change follows a major reorganization that previously affected 365 employees across facilities in the United States, China, the Netherlands, and Switzerland.
Timeline
2022: Galapagos acquired AboundBio for 14 million dollars.
October 2025: Lakefront Biotherapeutics officially exited the cell therapy sector.
November 2025: CEO Henry Gosebruch addressed the closure of the cell therapy division.
March 2026: Gilead Sciences provided Ouro Medicines' TCE technology to Lakefront.
October 15, 2026: Lakefront announced the sale of its remaining cell therapy assets.
The Tech Race
This deal underscores the industry-wide consolidation toward high-efficiency T-cell engager research. It follows the strategic pattern set by Gilead Sciences' 1.67 billion dollar acquisition of Ouro Medicines as companies move to streamline their portfolios.
The change moves preclinical development responsibility to Armed Cell Therapeutics, which now controls the future progression of these specific therapies. Researchers and investors should monitor upcoming disclosures regarding the specific disease targets these programs intend to address.
The takeaway
The sector shift highlights the transition of cell therapy assets to independent developers while major firms consolidate their focus on T-cell engagers. Watch for the next milestone update from Armed Cell Therapeutics to assess the viability of the transferred programs.
Further reading
For broader insights into the competitive landscape, visit the /tech/biotech/ section.
Live Poll
Do you trust that major pharmaceutical companies are effectively managing their research and development investments?
